{"name":"Enochian Biosciences","slug":"enochian","ticker":"ENOB","exchange":"NASDAQ","domain":"enochianbiosciences.com","description":"Enochian Biosciences is a clinical-stage cell and gene therapy company focused on developing treatments for various diseases. The company's pipeline includes several promising candidates, with a strong emphasis on oncology and rare genetic disorders. As a relatively new player in the industry, Enochian Biosciences is positioned to capitalize on the growing demand for innovative therapies. With a strong management team and a robust pipeline, the company is well-positioned for future growth.","hq":"Los Angeles, CA","founded":0,"employees":"","ceo":"Luisa Puig","sector":"Clinical-Stage Cell & Gene Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":537428,"netIncome":-178007489,"cash":92700,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"EB-001 patent cliff ($0.0B at risk)","drug":"EB-001","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"EB-002 patent cliff ($0.0B at risk)","drug":"EB-002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Enochian Biosciences Announces FDA Clearance of IND for EB-001","summary":"Enochian Biosciences announced that the FDA has cleared the Investigational New Drug (IND) application for EB-001, a novel cell therapy for the treatment of certain types of cancer.","drugName":"EB-001","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Enochian Biosciences Reports Third Quarter 2022 Financial Results","summary":"Enochian Biosciences reported its financial results for the third quarter of 2022, with a focus on its pipeline development and operational progress.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Enochian Biosciences Enters into Collaboration Agreement with Leading Research Institution","summary":"Enochian Biosciences announced a collaboration agreement with a leading research institution to advance the development of its cell therapy pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNNkM2Q1JjZVNLV3FYYTJPUmQyQnBYVWNva0p3VDgzNkp0ZmhaYW9TMThBYzNmdGlDZjhuSGFOREdERzdja3J4Qng1WXZPR290T2FNa2REbTR3UmJQZW9ST2tHX0dFdVB4dXlLYzlIUmFsWmIwTzFqYW1sQ094QklKdWJmUXJBNzk5Y01rclVDV1drV3JIbHM3RjVkMjJqQ2FaNS1rOFRlNkotRFc4MktHQXhXekFlSnVmQjM5TzdETDR1Zw?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"Enochian Biosciences stock: Why this biotech bet keeps drawing investor eyes - AD HOC NEWS","headline":"Enochian Biosciences stock: Why this biotech bet keeps drawing investor eyes","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPZldtMUU3cXZRZ1VkSmVkVFF4RE1vdGlPN0hvQXY5ZGswVVllTnRZTnhtaUJ0bXVaUUhMaXhaXzM5dmhGQlhfMEM4RDJZZHBlOTZZNTZLT0FTdFBVTi1MdXJPcjh3aXVkOHdjMnp1Tk45WG9aVnpWemdjWHh4OXBFdmxBNnVTUzQtUFhfcjZnQVlyLVZ4VUVjYkh2U2h1VlpHTmFaUG5hWVJXRHlXWk9obm5fcll2Q3FOUV9YYjZSS3Z2dGY1T0RJ?oc=5","date":"2026-03-22","type":"trial","source":"AD HOC NEWS","summary":"Enochian Biosciences stock faces volatility amid clinical trial delays and biotech sector pressures - AD HOC NEWS","headline":"Enochian Biosciences stock faces volatility amid clinical trial delays and biotech sector pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVzh1T283M1dRR0RKakxiQVVlVmtvQXBQNldEVVpiei01d2lvLS1KRENSYjNLYjcxNlltdHpoLURGMnREaENoZFhPSGdsVFNzT3U2U1I4c3JVaVQ3R1BqOVM3cDlIdVJpcGhRNEUwZmJkZmRKSkg4VEp1OUNZaFg5ZFVOamx4STBSSmM1U012eGN5UXZTQjhOeUJpTWlQR2tzVGpkd0gtbGJ4aktXTEtKUTJSRktaR01jLTU1NXFpUmY?oc=5","date":"2026-03-16","type":"pipeline","source":"AD HOC NEWS","summary":"Enochian Biosciences Stock (ISIN: US29359T1097) Faces Mounting Liquidity Challenges Amid Biotech Hea - AD HOC NEWS","headline":"Enochian Biosciences Stock (ISIN: US29359T1097) Faces Mounting Liquidity Challenges Amid Biotech Hea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSm1Zc19jUDE2SEdDSGtkTDV5bUdiLXFxbEhlbzJyQWxmN2I1MTJULXpKY3lWd01lOFpJNW9LY1VqeEYwTVVUd1IxalRjdDNXd3dTQ3k4MDViRXpRQzdaX3MxOC1KbWtTMXV3NjhiNl9YUFcxYTFmVjNEWnBmQ18zQzhaSXZKX1RpUVZkZUlreEVYdEpwcldvQ2dLNnVnQlJxMVFPUFpkQm5mOWszLVhKNDZPTHNuTU55Ry1nRHZsTW1wQQ?oc=5","date":"2026-03-15","type":"pipeline","source":"AD HOC NEWS","summary":"Enochian Biosciences Stock (ISIN: US29359T1097) Faces Mounting Challenges Amid Biotech Volatility - AD HOC NEWS","headline":"Enochian Biosciences Stock (ISIN: US29359T1097) Faces Mounting Challenges Amid Biotech Volatility","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"EB-001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"EB-002","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["CRISPR Therapeutics","Editas Medicine","Bluebird Bio"],"therapeuticFocus":["Oncology","Rare Genetic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2012-03-31","revenueHistory":[{"value":0,"period":"2012-03-31"},{"value":0,"period":"2011-03-31"}],"grossProfit":37494,"grossProfitHistory":[],"rdSpend":537428,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-178007489,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":92700,"cashHistory":[],"totalAssets":8230840,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}